Add to ORKGPalonosetron: an evidence-based choice in prevention of nausea and vomiting induced by moderately emetogenic chemotherap
BACKGROUND: APF530 is a novel sustained-release formulation of granisetron. In a Phase III trial, AP...
BACKGROUND: APF530 is a novel sustained-release formulation of granisetron. In a Phase III trial, AP...
BACKGROUND: APF530 is a novel sustained-release formulation of granisetron. In a Phase III trial, AP...
Palonosetron: an evidence-based choice in prevention of nausea and vomiting induced by moderately em...
Introduction: The second-generation 5-hydroxytryptamine-3 (5-HT3) receptor antagonist palonosetron i...
Aims and background. In 2003, the second-generation, 5-HT3 receptor antagonist (5-HT3 RA) palonosetr...
Significant progress has been made in the development of effective, convenient and well-tolerated me...
The content of this article has been reviewed by independent peer reviewers to ensure that it is bal...
Background: Despite advances in symptom management, chemotherapy-induced nausea and vomiting (CINV) ...
Abstract Background Nausea is more difficult to control than vomiting in chemotherapy. We therefore ...
Abstract: Palonosetron, the second generation 5-hydroxytryptamine-3 receptor antagonist (5-HT3RA), h...
In this update of our 2005 document, we used an evidence-based approach whenever possible to formula...
Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemoth...
Background The combination of a neurokinin-1 receptor antagonist, dexamethasone, and a 5-HT(3) recep...
Clinical update on palonosetron in the management of chemotherapy-induced nausea and vomitin
BACKGROUND: APF530 is a novel sustained-release formulation of granisetron. In a Phase III trial, AP...
BACKGROUND: APF530 is a novel sustained-release formulation of granisetron. In a Phase III trial, AP...
BACKGROUND: APF530 is a novel sustained-release formulation of granisetron. In a Phase III trial, AP...
Palonosetron: an evidence-based choice in prevention of nausea and vomiting induced by moderately em...
Introduction: The second-generation 5-hydroxytryptamine-3 (5-HT3) receptor antagonist palonosetron i...
Aims and background. In 2003, the second-generation, 5-HT3 receptor antagonist (5-HT3 RA) palonosetr...
Significant progress has been made in the development of effective, convenient and well-tolerated me...
The content of this article has been reviewed by independent peer reviewers to ensure that it is bal...
Background: Despite advances in symptom management, chemotherapy-induced nausea and vomiting (CINV) ...
Abstract Background Nausea is more difficult to control than vomiting in chemotherapy. We therefore ...
Abstract: Palonosetron, the second generation 5-hydroxytryptamine-3 receptor antagonist (5-HT3RA), h...
In this update of our 2005 document, we used an evidence-based approach whenever possible to formula...
Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemoth...
Background The combination of a neurokinin-1 receptor antagonist, dexamethasone, and a 5-HT(3) recep...
Clinical update on palonosetron in the management of chemotherapy-induced nausea and vomitin
BACKGROUND: APF530 is a novel sustained-release formulation of granisetron. In a Phase III trial, AP...
BACKGROUND: APF530 is a novel sustained-release formulation of granisetron. In a Phase III trial, AP...
BACKGROUND: APF530 is a novel sustained-release formulation of granisetron. In a Phase III trial, AP...